Page last updated: 2024-09-03

gefitinib and imiquimod

gefitinib has been researched along with imiquimod in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(imiquimod)
Trials
(imiquimod)
Recent Studies (post-2010) (imiquimod)
5,2315662,9193,2642841,963

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)imiquimod (IC50)
Histamine H2 receptorHomo sapiens (human)1.506
Alpha-1D adrenergic receptorHomo sapiens (human)2.621
Adenosine receptor A2aHomo sapiens (human)5.32
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)0.646

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bogeschdorfer, F; Gronau, S; Riechelmann, H1

Reviews

1 review(s) available for gefitinib and imiquimod

ArticleYear
[New substances in the therapy of head and neck cancer].
    Laryngo- rhino- otologie, 2006, Volume: 85, Issue:7

    Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration

2006

Other Studies

1 other study(ies) available for gefitinib and imiquimod

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013